Skip to main content

Table 1 Change in tumor volume before and after treatment

From: The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

Group

Volume Week 1 (mm3)

Volume Week 12 (mm3)

Volume change (mm3)

Control

65 ± 15.3

1447.7 ± 291.3

1382.7 ± 276

Bz alone

104 ± 6.6

1049.4 ± 381

945.4 ± 374.4

Bz → HB

104 ± 9.7

702.3 ± 260.3

598.3 ± 250.5

HB → Bz

64.6 ± 7.5

538.5 ± 281.5

473.9 ± 274.1

  1. Mean tumor volumes ± SEM are listed for each group at weeks 1 and 12 of the study. Change in tumor volume between week 1 and week 12 are listed in the final column. The arrow denotes the order of treatment. Bz = Bortezomib, HB = HB 22.7. n = 5 mice per group
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us